Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
100 participants
INTERVENTIONAL
2016-05-31
2016-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Morphine Versus Ketorolac in Low Back Pain
NCT02782286
IV Ketorolac on Platelet Function Post-Cesarean Delivery
NCT03805607
Intravenous Ketorolac for Postoperative Pain in Laparoscopic Donor Nephrectomy
NCT00765232
Modulation of Remifentanil-induced Postinfusion Hyperalgesia
NCT00785863
Multimodal Analgesia in Major Abdominal Pediatric Cancer Surgeries
NCT03580980
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The patients will be randomised to receive either ketorolac 30 mg intravenous (diluted in 20 ml of 0,9% saline) or morphine 0,1 mg/kg weight intravenous. A scale of 1-10 will be used for measuring the pain, and the effects of the treatment will be evaluated at 15 minutes and 30 minutes from the administration of the drugs. After 30 minutes if there is no significant reduction of the pain a rescue therapy will be used : chlorhydrate drotaverine 40 mg, xilocaine 100 mg, both diluted in 100 ml saline and the other medication not used from the study (morphine or ketorolac tromethamine).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ketorolac
The patients randomised to this arm they will receive 30 mg intravenous ketorolac.
Morphine
The patients randomised to this arm they will receive 0,1 mg/kg intravenous morphine.
Morphine
The patients randomised to this arm they will receive 0,1 mg/kg intravenous morphine.
Ketorolac
The patients randomised to this arm they will receive 30 mg intravenous ketorolac.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ketorolac
The patients randomised to this arm they will receive 30 mg intravenous ketorolac.
Morphine
The patients randomised to this arm they will receive 0,1 mg/kg intravenous morphine.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* grade 5 pain on a 1-10 visual pain scale
Exclusion Criteria
* pregnancy
* allergies to ketorolac or opioids
* refusal of participation
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Loredana Ghinea
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Loredana Ghinea
Medical Doctor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dan Marinescu, MD
Role: PRINCIPAL_INVESTIGATOR
Clinical Emergency Hospital Bucharest
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1-4627
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.